# TRADE DXd (NCT06533826)

> TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06533826
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Ana C Garrido-Castro, MD
- Conditions: Breast Cancer; HER2-low Breast Cancer; Metastatic Breast Cancer; HER2-negative Breast Cancer
- Interventions: Trastuzumab Deruxtecan; Datopotamab Deruxtecan
- Enrollment: 357
- Primary outcome: Objective Response Rate in ADC1 (Group 1) Cohort
- Primary outcome: Objective Response Rate in ADC2 (Group 2) Cohort

## Commentary we found

- YouTube: 24
- Podcasts: 22
- X threads: 7

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=trade-dxd-nct06533826

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06533826", "email": "<work email>"}; the inbox owner confirms by the emailed link.